As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Electra Therapeutics, Inc. The largest reported stake is Orbimed Advisors LLC's, at 11%. 4 filings are on record since September 25, 2026 (Schedule 13D, September 25, 2026).
Sell to companies like Electra Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Westlake BioPartners Fund I, L.P. · Sole voting: 3,527,136 · Shared voting: 3,527,136 · Sole dispositive: 3,527,136 · Shared dispositive: 3,527,136 · SCHEDULE 13G, 2026-10-29
- · Reporting person: Redmile Group, LLC · Sole voting: 0 · Shared voting: 5,462,881 · Sole dispositive: 0 · Shared dispositive: 5,462,881 · SCHEDULE 13G, 2026-09-28
- · Reporting person: LSP 7 Cooperatief U.A. · Sole voting: 0 · Shared voting: 3,795,281 · Sole dispositive: 0 · Shared dispositive: 3,795,281 · SCHEDULE 13G, 2026-09-28
- · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 6,885,170 · Sole dispositive: 0 · Shared dispositive: 6,885,170 · SCHEDULE 13D, 2026-09-25
Electra Therapeutics, Inc. has 4 Schedule 13D or 13G filings on record since 2026-09-25. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Orbimed Advisors LLC | 11% | 6,885,170 | SCHEDULE 13D, 2026-09-25 | 2026-09-21 |
| 10.1% | 6,347,539 | SCHEDULE 13G, 2026-10-29 | 2026-09-30 | |
| Redmile Group, LLC | 8.7% | 5,462,881 | SCHEDULE 13G, 2026-09-28 | 2026-09-21 |
| LSP 7 Cooperatief U.A. | 6% | 3,795,281 | SCHEDULE 13G, 2026-09-28 | 2026-09-21 |
Holding shares or following this stake? See who's behind Electra Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Electra Therapeutics, Inc. and the records around it.
Electra Therapeutics, Inc. elsewhere on the record
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Westlake BioPartners Fund I, L.P. also filed stake reports on 2 other companies: Latigo Biotherapeutics, Inc. (Oct 2026), Kyverna Therapeutics, Inc. (Feb 2026)
- LSP 7 Cooperatief U.A. also filed stake reports on 3 other companies: Oculis Holding AG (Apr 2026), Evommune, Inc. (Feb 2026), AgomAb Therapeutics NV (Feb 2026)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Neurogene Inc. (Aug 2026), Nurix Therapeutics, Inc. (Aug 2026)
Watch Electra Therapeutics, Inc.
Get an email when Electra Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Electra Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Electra Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Electra Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 0 | 6,885,170 | 0 | 6,885,170 | SCHEDULE 13D, 2026-09-25 |
| Orbimed Capital Gp Vii LLC | 0 | 5,126,891 | 0 | 5,126,891 | SCHEDULE 13D, 2026-09-25 |
| OrbiMed Genesis GP LLC | 0 | 1,758,279 | 0 | 1,758,279 | SCHEDULE 13D, 2026-09-25 |
| Westlake BioPartners Fund I, L.P. | 3,527,136 | 3,527,136 | 3,527,136 | 3,527,136 | SCHEDULE 13G, 2026-10-29 |
| Westlake BioPartners GP I, LLC | 3,527,136 | 3,527,136 | 3,527,136 | 3,527,136 | SCHEDULE 13G, 2026-10-29 |
| Westlake BioPartners Fund II, L.P. | 2,820,403 | 2,820,403 | 2,820,403 | 2,820,403 | SCHEDULE 13G, 2026-10-29 |
| Westlake BioPartners GP II, LLC | 2,820,403 | 2,820,403 | 2,820,403 | 2,820,403 | SCHEDULE 13G, 2026-10-29 |
| Dr. Beth C. Seidenberg | 6,347,539 | 6,347,539 | 6,347,539 | 6,347,539 | SCHEDULE 13G, 2026-10-29 |
| Redmile Group, LLC | 0 | 5,462,881 | 0 | 5,462,881 | SCHEDULE 13G, 2026-09-28 |
| Jeremy C. Green | 0 | 5,462,881 | 0 | 5,462,881 | SCHEDULE 13G, 2026-09-28 |
| Redmile Biopharma Investments II, L.P. | 0 | 4,796,215 | 0 | 4,796,215 | SCHEDULE 13G, 2026-09-28 |
| LSP 7 Cooperatief U.A. | 0 | 3,795,281 | 0 | 3,795,281 | SCHEDULE 13G, 2026-09-28 |
| LSP 7 Management B.V. | 0 | 3,795,281 | 0 | 3,795,281 | SCHEDULE 13G, 2026-09-28 |
The latest filing identifies Electra Therapeutics, Inc. by CUSIP 284825106 and gives its principal executive office as 230 East Grand Avenue, Suite S-100, South San Francisco, CA 94080 (SCHEDULE 13G, 2026-10-29).
Source of funds (Item 3)
In February 2022, OrbiMed Advisors and OrbiMed GP, pursuant to their authority under the limited partnership agreement of OrbiMed Private Investments VII, LP ("OPI VII"), cause OPI VII to purchase 1,632,119 shares of Series B Preferred Stock. In October 2025, OrbiMed Advisors and OrbiMed GP caused OPI VII to purchase 2,038,237 shares of Series C Preferred Stock. In June 2026, OrbiMed Advisors and OrbiMed GP caused OPI VII to purchase a second tranche of 517,078 shares of Series C Preferred Stock.Orbimed Advisors LLC, SCHEDULE 13D, 2026-09-25
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-25; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-09-25 | Orbimed Advisors LLC | 11% | SCHEDULE 13D |
| 2026-09-28 | Redmile Group, LLC | 8.7% | SCHEDULE 13G |
| 2026-09-28 | LSP 7 Cooperatief U.A. | 6% | SCHEDULE 13G |
| 2026-10-29 | Dr. Beth C. Seidenberg | 10.1% | SCHEDULE 13G |
Questions about who owns Electra Therapeutics, Inc.
Who owns Electra Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Electra Therapeutics, Inc.: Orbimed Advisors LLC (11%, Schedule 13D, filed 2026-09-25), Dr. Beth C. Seidenberg (10.1%, Schedule 13G, filed 2026-10-29), Redmile Group, LLC (8.7%, Schedule 13G, filed 2026-09-28) and LSP 7 Cooperatief U.A. (6%, Schedule 13G, filed 2026-09-28).
Who are the largest shareholders of Electra Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Electra Therapeutics, Inc. on this page are Orbimed Advisors LLC (11%), Dr. Beth C. Seidenberg (10.1%) and Redmile Group, LLC (8.7%).
When did Orbimed Advisors LLC buy into Electra Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D, filed 2026-09-25, reporting 11%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Electra Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 18, 2026 | IPO filing, Form 424B4 | $15 a share | IPO filings | Source |
| September 14, 2026 | IPO filing, Form S-1/A | $14 to $16 a share | IPO filings | Source |
| August 28, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| October 30, 2025 | Form D, private offering | $134.19M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Electra Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.